Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Class: Antineoplastic Agents
Brands: Phesgo
Warning
WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY
See full prescribing information for complete boxed warning.
Cardiomyopathy: Fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf administration can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue the fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for cardiomyopathy.
Embryo-fetal Toxicity: Exposure to the fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.
Pulmonary Toxicity: Discontinue the fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
Introduction
The fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf is an antineoplastic agent.
Uses for Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf has the following uses:
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer; or as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
The fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf also is used in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Dosage and Administration
General
The fixed combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf is available in the following dosage form(s) and strength(s):
Injection:
1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial.
600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL (60 mg, 60 mg, and 2,000 units/mL) of solution in a single-dose vial.
Dosage
It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults
Dosage and Administration
...
